Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
Treatment of systemic lupus erythematosus should be individualized according to disease severity, type of organ involvement, and degree of activity. It includes drug therapy, cell therapy, lifestyle management, and rehabilitation measures, aiming to suppress abnormal immune responses, protect organ function, and improve long-term quality of life.
Europe and the United States
In Europe and the United States, the incidence of systemic lupus erythematosus is about 20 to 70 cases per 100,000 people, with women accounting for more than 90% of patients. Advances in diagnostic technology over the past 20 years have improved early detection rates, but treatment adherence remains one of the key factors affecting prognosis.
Southeast Asia
In Southeast Asian countries, the incidence is about 15 to 50 cases per 100,000 people. In some regions with limited medical resources, patients are often diagnosed at middle or late stages. Hot and humid environments and genetic factors are considered important contributors to the higher incidence in this region.
Immune reconstruction cell therapy restores patients’ immune balance by reinfusing healthy immune cells, reducing inflammatory responses and autoantibody attacks, thereby protecting vital organ function. This therapy enables targeted immune regulation, reduces long-term drug dependence, and has demonstrated good safety and tolerability in multiple clinical practices, offering patients a new treatment direction.
1. Efficient immune regulation
Cell therapy can precisely identify and clear abnormal immune cells while preserving normal immune function, reducing the risk of systemic immunosuppression caused by traditional drugs.
2. Improved organ protection
In systemic lupus erythematosus involving multiple organs, cell therapy helps reduce involvement of the kidneys, heart, and other organs, lowering the rate of irreversible damage.
3. Enhanced quality of life
Cell therapy can reduce relapse frequency and shorten flare durations, enabling patients to achieve more stable disease control and living conditions.
In actual treatment, patients undergoing traditional regimens often face immune dysfunction, increased infection risks, and slow recovery. To help patients better sustain the treatment process, improve tolerance, and enhance quality of life, phased immune reconstruction programs must be scientifically designed for different treatment cycles.
● Short-term plan: Rapidly enhance immunity through immune cell reinfusion to strengthen anti-disease effects.
● Mid-term plan: Reduce side effects of conventional treatments, promote recovery, and ensure completion of standardized regimens.
● Long-term plan: Comprehensive enhancement of immunity through immune cell reconstruction, gut immunity restoration, elemental immunity rebuilding, and immune nutrition support, thereby improving quality of life and prolonging survival.
1. Glucocorticoid therapy
Rapidly controls inflammation and relieves symptoms, commonly used during acute flare-ups, but long-term use requires caution against side effects such as osteoporosis.
2. Immunosuppressants
Such as cyclophosphamide and mycophenolate mofetil, used to control moderate to severe disease and organ involvement, reducing excessive immune attacks.
3. Antimalarials
Such as hydroxychloroquine, suitable for long-term maintenance therapy, reducing relapse risk and improving skin and joint symptoms.
4. Biologics
Drugs designed for specific immune pathways, such as belimumab, can precisely inhibit abnormal B cell activity.
5. Supportive therapy
Including antihypertensive drugs, anticoagulants, and bone-protective agents, to reduce complications and improve quality of life.
6. Rehabilitation and lifestyle interventions
Moderate exercise, a reasonable diet, and psychological counseling help improve immunity and relieve anxiety.
7. Regular monitoring
Laboratory tests and imaging assessments should be conducted to promptly adjust treatment regimens and maintain disease stability.
8. Multidisciplinary management
Collaboration among rheumatology, nephrology, cardiology, and other departments provides more precise and comprehensive treatment strategies.
Systemic lupus erythematosus is a chronic, recurrent, and multi-organ autoimmune disease. Without timely treatment, it may cause severe complications or even become life-threatening. Combining multiple treatment approaches is essential for achieving optimal control. Experts at United Life International Medical Center emphasize that scientific treatment and continuous management can significantly improve patient outcomes and extend survival.
